FEDERALhearing transcript

Senate Hearing: Speeding Up Treatments for Rare Diseases

Original title: RARE DISEASES: EXPEDITING TREATMENTS FOR PATIENTS

January 1, 2020

rare diseases orphan drugs FDA regulation healthcare policy medical research

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing explores potential changes to federal drug approval processes that could shorten the time and reduce the costs required to bring new treatments for rare diseases to patients.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Patients with rare diseases

These individuals face limited access to treatments for life-threatening conditions due to current drug approval timelines.

Pharmaceutical companies

These entities must navigate FDA regulatory requirements and high development costs to bring orphan drugs to market.

What changed

Last recorded activity January 1, 2020.

What's next

Next step not available in the current record.

Summary

This Senate subcommittee hearing examined the regulatory hurdles that delay the approval of 's'—medications designed to treat rare conditions. Lawmakers and medical experts discussed how current FDA approval processes for rare diseases can take over a decade and cost billions, leaving many patients without access to life-saving treatments.

Key Facts

The FDA defines an 'orphan disease' as a condition affecting fewer than 200,000 patients in the United States.
There are over 7,000 identified rare diseases affecting approximately 30 million Americans.
Approximately 90% of rare diseases are considered serious or life-threatening.
Most rare diseases currently lack an FDA-approved treatment.
Developing a new drug can take up to a decade and cost upwards of $2 billion.
The hearing was held on October 3, 2018, by the Subcommittee on Children and Families.
Current regulatory standards for orphan drugs are largely the same as those for common conditions.

Frequently Asked Questions

What is an orphan drug?

An is a medication developed specifically to treat a rare disease, which the FDA defines as a condition affecting fewer than 200,000 people.

Why is it difficult to get treatments for rare diseases?

The hearing noted that the approval process is lengthy and expensive, often taking over 10 years and costing billions of dollars, with the same regulatory requirements applied to rare diseases as to common ones.

Why It Matters

The hearing explores potential changes to federal drug approval processes that could shorten the time and reduce the costs required to bring new treatments for rare diseases to patients.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Regulatory parity concerns

The hearing highlights a tension between applying uniform safety standards to all drugs versus creating specialized, faster pathways for rare disease treatments.

Food and Drug Administration

Connected Entities

organizationIntraBio, Inc.“Represented by founder Mallory Factor”Map →

personRand Paul“Chairman of the Subcommittee on Children and Families”Map →

personRobert P. Casey, Jr.“Ranking Member of the Subcommittee”Map →

organizationFood and Drug Administration“The federal agency responsible for drug approval”Map →

organizationEveryLife Foundation for Rare Diseases“Represented by witness Mark Dant”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance65
How much this matters to a regular citizen
Controversy20
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz15
Current news / social attention level

Publisher tools